Oxford Nanopore Technologies: John Schoellerman

Aug 07, 2019

John Schoellerman has joined Oxford Nanopore Technologies as senior vice president of corporate development and investment. Previously, he was managing director and head of medtech at Lazard, and before that, he worked in healthcare investment banking at JP Morgan. Schoellerman holds a BA from Harvard University and an MBA from INSEAD.

Breaking News

SARS-CoV-2 Variants of Concerns Evolved to Modify Host Immune Response, Multiomics Study Shows
People in the News at GA4GH, Mercy BioAnalytics, Deepcell, One Biosciences
New Products Posted to GenomeWeb: Clinical Microbiomics, Integra Biosciences, DNAstack, Bruker
Angolan Namib Desert Population Analysis Uncovers New Ancestry Group With Deep Divergence
Cedars-Sinai Sets Up $25M Single Cell Precision Medicine Center

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.